American firm Novavax starts late-stage trial of Covid-19 vaccine in US and Mexico
The vaccine can be stored between two and eight degrees Celsius, meaning it could be more easily distributed than competitors. By AFP Monday 28 Dec 2020, 10:53 PM Dec 28th 2020, 10:53 PM 19,263 Views 24 Comments
Image: SIPA USA/PA Images
Image: SIPA USA/PA Images
CLINICAL TRIALS TO determine the safety and efficacy of a Covid-19 vaccine candidate from American biotech company Novavax have begun in the United States and Mexico, the US National Institutes of Health (NIH) announced today.
A similar Phase 3 trial for the same vaccine, called NVX-CoV2373, is also under way in the United Kingdom, where about 15,000 volunteers have been recruited.
Crawford County has Iowa s third-highest COVID-19 positivity rate siouxcityjournal.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from siouxcityjournal.com Daily Mail and Mail on Sunday newspapers.
The Phase 3 trial of another investigational Covid-19 vaccine developed by biotechnology company Novavax, Inc., has started enrolling adult volunteers, the US National Institutes of Health (NIH) announced. In a statement issued on Monday, the NIH said that the randomised, placebo-controlled trial will enrol approximately 30,000 people at some 115 sites in the US and Mexico, reports Xinhua news agency. It will evaluate the safety and efficacy of NVX-CoV2373, the vaccine candidate. Volunteers will be asked to give informed consent prior to their participation in the trial, according to the NIH statement. They will be grouped into two cohorts: individuals 18 through 64 years old and those aged 65 and older, with a goal of enrolling at least 25 percent of all volunteers who are 65 years old or older, it said.
Israel G Vargas
“It’s time to get rid of the scars,” says Mark Slack, a gynaecologist and co-founder of robotic surgery startup CMR Surgical. Cambridge-based CMR Surgical was founded in 2014 – Slack remembers how, when the company started, surgeons wanted a robot that was suitable for all surgical disciplines: equivalent in cost to a straight-stick surgery, adaptable to any theatre, modular and quick to set up and take down. “There was nothing like it,” he says. “So what did we do? We had to build our own robot.” The result is the Versius, a surgical robot designed to help surgeons perform keyhole surgery. Today, the company employs around 500 people and, after raising more than $100 million (£75.2 million) in June 2018, it’s now valued at more than $1 billion (£759 million), making it one of the rare unicorns in medtech.